Abstract: A method and a test for detecting coagulation activation, in particular when it is responsible for thromboembolic venous diseases; employs assaying D-dimers and assaying the soluble fibrin produced during a fibrinolysis process activated in a blood sample. The method of the invention pertains to comparing the level of D-dimers corresponding to degradation of soluble fibrin and the level of D-dimers of the sample with normal threshold values. The test of the invention may also be used to determine whether anti-coagulation is sufficient in a patient.

Abstract: A method is provided for adjusting either the signal measured or activity calculated by an instrument or a predefined calibration curve for a medical diagnostic test, performed on an instrument with pre-calibrated reagents. A calibration adjuster for a blood clotting diagnostic test is further provided.

Abstract: A reaction well, intended for use in an automatic analysis appliance and including an opening at its top end and one or two flaps for partially closing said opening, the flaps being separated by a slot enabling a liquid injection or sampling needle to pass through, and preventing stirrer means contained within the well from escaping.

Abstract: The invention relates to a drive arrangement for a series of cuvettes (C) forming a strip (2) fixed by means of a film (3) in an automatic analytical device (1), comprising at least one toothed belt (12), the teeth of which engage with the corresponding forms of the cuvettes. The above finds application in an automatic analytical device, particularly for the determination of the rate of change of the physical state of a medium.

Abstract: A method and a test for detecting coagulation activation, in particular when it is responsible for thromboembolic venous diseases; employs assaying D-dimers and assaying the soluble fibrin produced during a fibrinolysis process activated in a blood sample. The method of the invention pertains to comparing the level of D-dimers corresponding to degradation of soluble fibrin and the level of D-dimers of the sample with normal threshold values. The test of the invention may also be used to determine whether anti-coagulation is sufficient in a patient.

Abstract: The invention relates to a drive arrangement for a series of cuvettes (C) forming a strip (2) fixed by means of a film (3) in an automatic analytical device (1), comprising at least one toothed belt (12), the teeth of which engage with the corresponding forms of the cuvettes. The above finds application in an automatic analytical device, particularly for the determination of the rate of change of the physical state of a medium.

Abstract: The invention concerns a method for the quantitative measurement of at least one analyte of interest in a liquid sample by immunochromatography, said method comprising weighted measurement of the quantity of analyte with respect to a control. The method is of particular application to medical diagnostics in the field of hemostasis, for example to exclude a risk of diagnosis of venous thromboembolic disease.

Abstract: The invention relates to chromogenic compounds and the use thereof for the determination of enzymes of the family of carboxypeptidases N and carboxypeptidases U. The above is more specifically a compound of formula (I) in which A=(1), (2), (3), (4) or (5), R1, R2=H, —CH3, —CH(CH3)2, —OCH3, —Cl,—CF3,—OCF3,—SCH3, R3=an amino acid group which may be hydrolysed by a carboxypeptidase A and R4=a basic amino acid group.

Abstract: The invention concerns a method for detecting and/or quantifying at least an analyte in a liquid medium, characterized in that it consists in using magnetic colloidal particles functionalized at the surface with at least a ligand specific of the analyte to be detected and/or assayed and in that it comprises: contacting said particles with said medium to be analyzed; applying a magnetic field to said medium, at an intensity sufficient to cause said magnetic particles to be structured in the form of chains; maintaining said magnetic field for a sufficient time interval to enable coupling or combination of the analyte concerned with at least two specific ligands present respectively on two neighbouring particles of a chain; cancelling the magnetic field, and determining the presence and/or absence of said analyte and, as the case may be, its concentration via the presence and/or the absence of said permanent chains of magnetic particles.

Abstract: The invention concerns contact activators for the endogenous coagulation pathway and their use in exploring coagulation anomalies. The activators of the invention are derivatives of gallic acid, preferably polyethylene glycol gallates.

Abstract: The invention relates to chromogenic compounds and the use thereof for the determination of enzymes of the family of carboxypeptidases N and carboxypeptidases U. The above is more specifically a compound of formula (I) in which A=(1), (2), (3), (4) or (5). R1. R2=H. —CH3, —CH(CH3)2, —OCH3, —Cl.—CF3,—OCF3,—SCH3, R3=an amino acid group which may be hydrolysed by a carboxypeptidase A and R4=a basic amino acid group.

Abstract: The invention concerns a compound exhibiting an anti-heparin activity, of formula ZBm?(AXA)xBn?(AXA)yBo(AXA)zBp, the diagnostic reagents comprising it and the use of said compound in an in vitro diagnostic test of a medicine for anti-heparin activity.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: The invention concerns contact activators for the endogenous coagulation pathway and their use in exploring coagulation anomalies.

Abstract: A method provides for the placing of samples containers inside holders, a first displacement bringing the holders to an zone with access to the blood analyser pipetting area, identifying the containers during this displacement, a second rectilinear displacement through the pipetting zone along a path perpendicular to the first, a third rectilinear displacement bringing the holders to a second zone acceding to the pipetting area a fourth displacement through the pipetting area and bringing the holders to second outlet zone located on the first path and a path bringing the holder, to the first access zone or an evacuating zone. The method is particularly useful for carrying out hemostasis test on centrifuged blood samples.

Abstract: The invention concerns a seal for closing the neck of a flask. The seal comprises a stopper with a central coaxial channel for passage of an injection and/or sampling needle, this channel being sealed by at least one ball with a diameter slightly greater than that of the channel. This seal is suitable for a reagent flask used by a blood analyzer.

Abstract: A process for determining a resistance to activated protein C of a test specimen of human plasma following the steps of: (1) mixing together (a) the test specimen of human plasma, (b) a reactant deficient in factor V which supplies at least most of the coagulation factors other than factor V, and (c) the venom of Crotalus viridis helleri which specifically activates factor X to Xa, and incubating the mixture of (a), (b) and (c) for at least one minute at a temperature of between 10 and 45° C.; (2) introducing into the incubated mixture(i) Ca2+ or (ii) Ca2++exogenic activated protein C; and (3) determining the coagulation time (i) in the absence of activated protein C and (ii) in the presence of activated protein C. Steps (1) to (3) are repeated, but replacing, in step (1), the test specimen with a normal plasma as control and correlating resistance to activated protein C by comparing the determinations made in steps for the test specimen and for the normal plasma.

Abstract: The invention relates to the use of a serum rich in factor Va for the preparation of compositions useful as pathological controls or calibrants in methods for analyzing resistance to activated protein C (APC), as well as said compositions, the method for their preparation and a method for the detection of resistance to activated protein C.